Evusheld Authorized: New COVID-19 Treatment
The FDA issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld™. Evusheld is a new COVID-19 treatment designed to prevent COVID-19 infection in vulnerable and immunocompromised individuals who may not have an adequate immune response to COVID-19 vaccination. In immunocompromised patients, a vaccination may not generate enough immunity so they are still able to have a severe infection.
Evusheld gives additional immunity to help prevent COVID-19. Evusheld is a combination of two monoclonal antibodies, given in two consecutive injections in one visit to qualifying patients who do not have COVID-19.
The FDA has given an EUA for this medicine to be given to those with specific illness or medical situations which puts them at high-risk of developing severe COVID-19 illness.
Eligibility Criteria:
Adults and pediatric individuals (12 years of age and older weighing at least 88 pounds 40 kg):
- Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2,
AND
- Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination,
OR
- Someone for whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).
For more information, click the cover to download a copy of the Fact Sheet.
Or utilize the PDF reader to click through pages here:
Evusheld-Patients-Parents-and-Caregivers-FS-02242022If you, or a person you support, could benefit from this treatment, please contact the primary physician to learn additional information.
